ArticleClinical, cosmetic and investigational dermatology2025
Topical Glucocorticoid-Induced Cushing's Syndrome in a Patient with Erythrodermic Psoriasis: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipomatosis From Prolonged Use of Corticosteroids in Ethiopia: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Topical glucocorticoids are widely used in psoriasis treatment but may lead to systemic adverse effects, particularly with prolonged use. While pediatric cases are well-documented, adult-onset iatrogenic Cushing's syndrome from topical corticosteroids remains under-recognized. Case Presentation: A 31-year-old woman with a 10-year history of psoriasis vulgaris self-administered high-potency clobetasol propionate ointment (monthly cumulative dose escalated from 30 g to 100 g over 22 months) under no physician supervision. She presented with erythrodermic psoriasis and Cushingoid features (moon facies, violaceous striae, pitting oedema). Laboratory tests confirmed suppressed cortisol (<1.5 nmol/L) and ACTH (2.86 pg/mL). Management included gradual withdrawal of topical steroids, initiation of oral methylprednisolone (8 mg daily) for HPA axis support, and transition to low-potency desonide. Four-month follow-up showed normalization of cortisol levels (167.1 nmol/L at 8:00 AM). Conclusion: This case highlights the systemic risks of unsupervised, escalating use of high-potency topical corticosteroids in adults with impaired skin barrier. It underscores the need for adherence to dosing guidelines, patient education, and routine endocrine monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.